# Higher Serum Free T4 Is Associated With Increased Risk of Mortality and Cerebrovascular Events in Elderly Men

**Authors:** Johan Svensson, Claes Ohlsson, Magnus K Karlsson, Åsa Tivesten, Hans Herlitz, Mattias Lorentzon, Catharina Lewerin, Dan Mellström

PMC · DOI: 10.1210/jendso/bvaf121 · Journal of the Endocrine Society · 2025-07-18

## TL;DR

Higher free T4 levels in elderly men with normal TSH are linked to higher risks of death and cerebrovascular events.

## Contribution

This study identifies serum free T4 as a predictor of mortality and cerebrovascular events in elderly men with normal TSH.

## Key findings

- Higher FT4 levels were associated with increased mortality risk in elderly men with normal TSH.
- FT4 was linked to increased cerebrovascular event risk, independent of atrial fibrillation.
- TSH levels were not associated with mortality, CVD events, or cancer risk.

## Abstract

It is unclear whether thyroid hormone levels are associated with the risk of mortality, cardiovascular disease (CVD) events, or cancer in men with normal TSH.

We analyzed if serum free T4 (FT4) or TSH is associated with the risk of mortality, incident CVD events, or cancer in Swedish men.

Elderly men (n = 1801; mean age 75 years) in the Gothenburg and Malmö subcohorts of the prospective, population-based Osteoporotic Fractures in Men Study-Sweden study were followed for median 12.2 years regarding all-cause mortality [1207 (67%) died] and for median 5.1 years regarding incident CVD events (n = 338) and cancer (n = 249). The statistical analyses included Cox proportional hazards regression with adjustment for covariates including prevalent atrial fibrillation (AF).

Serum FT4 (per SD increase) was associated with increased risk of mortality [men with normal TSH: fully adjusted hazard ratio (HR) 1.23, 95% confidence interval (CI): 1.11-1.35] and incident CVD events (HR 1.25, 95% CI: 1.05-1.48) but not with the risk of cancer. The association between FT4 and CVD events was mainly due to increased risk of cerebrovascular (CBV) events (HR 1.56, 95% CI: 1.24-1.96). Finally, TSH was not associated with the risk of mortality, CVD events, or cancer.

FT4, but not TSH, is a predictor of mortality risk in elderly men. The association between FT4 and elevated risk of CVD events was mostly due to increased risk of CBV events, which remained significant also after adjustment for prevalent AF.

## Linked entities

- **Diseases:** cardiovascular disease (MONDO:0004995), cancer (MONDO:0004992), atrial fibrillation (MONDO:0004981)

## Full-text entities

- **Genes:** APOB (apolipoprotein B) [NCBI Gene 338] {aka FCHL2, FLDB, LDLCQ4, apoB-100, apoB-48}, MROS (Melkersson-Rosenthal syndrome) [NCBI Gene 8011] {aka MRS}, APOA1 (apolipoprotein A1) [NCBI Gene 335] {aka AMYLD3, HPALP2, apo(a)}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}
- **Diseases:** breast cancer (MESH:D001943), acute MI (MESH:D000208), diabetes (MESH:D003920), thyroid disorder (MESH:D013959), hypothyroidism (MESH:D007037), heart failure (MESH:D006333), colon cancer (MESH:D015179), unstable angina (MESH:D000789), Osteoporotic Fractures (MESH:D058866), myocardial infarction (MESH:D009203), Hypertension (MESH:D006973), differentiated thyroid cancer (MESH:D013964), transient ischemic attack (MESH:D002546), CHD (MESH:D003327), ischemic stroke (MESH:D002544), dysrhythmias (MESH:D001145), stroke (MESH:D020521), impaired heart function (MESH:D006331), Cancer (MESH:D009369), angina pectoris (MESH:D000787), prostate cancer (MESH:D011471), Death (MESH:D003643), hyperthyroidism (MESH:D006980), AF (MESH:D001281), thyroid hormone dysfunction (MESH:D018382), CBV (MESH:D002561), CVD (MESH:D002318), basal cell carcinoma (MESH:D002280), Diseases (MESH:D004194)
- **Chemicals:** T4 (MESH:D013974), CBV (-), T3 (MESH:D014284), polyethylene glycol (MESH:D011092), lithium (MESH:D008094), amiodarone (MESH:D000638), lipid (MESH:D008055)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12308178/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12308178/full.md

## References

53 references — full list in the complete paper: https://tomesphere.com/paper/PMC12308178/full.md

---
Source: https://tomesphere.com/paper/PMC12308178